The pipeline for Inflammatory Bowel Disease (IBD) has an interesting assortment of novel agents, of which gastroenterologists are most familiar with Pfizer's Xeljanz, an oral JAK-inhibitor already approved for rheumatoid arthritis. Oral agents hold massive appeal in the IBD market with up to one-third of the gastroenterologists willing to accept lower efficacy for the convenience of a pill. Upon review of five IBD pipeline agents, more than one-third selected Celgene's mongersen as the most highly desired agent, followed by Xeljanz. Respondents were not so bullish on the profile of Roche/Genentech's etrolizumab. With about one-quarter of biologic-treated CD patients achieving suboptimal results, the opportunity for second and third-line agents looks very promising.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
About RealTime Dynamix
RealTime Dynamix™ is a quarterly service which combines large scale primary market research with unparalleled market understanding to dig deeper and seek out the latest opinions and controversies that are impacting autoimmune, renal and neurology markets.
For more information contact:
Lynn Price, Immunology Franchise Head
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-battle-for-preferred-alternative-mechanism-biologic-in-crohns-disease-heats-up-as-launch-of-janssens-stelara-approaches-the-six-month-mark-300426332.html
SOURCE Spherix Global Insights